Abstract | BACKGROUND: METHODS: Fifteen patients with biopsy-proven idiopathic membranous nephropathy resistant to conventional immunosuppressive therapy (n = 7) and/or ACEI treatment (n = 12) were recruited. Probucol (1 g/d orally) was administered for three months, followed by a washout period of four weeks, whereon lovastatin (10-20 mg/d orally) was administered for additional three months. RESULTS: A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6.4 (3.8-9.1) g/d vs. 4.7 (1.3-16) g/d; P < 0.05), with partial remission achieved in four patients. Three of these patients had previously been resistant to immunosuppressive therapy. Median protein excretion increased to pretreatment values during the washout period (6.2 (1.9-15) g/d; P < 0.05) and was not significantly different after the intake of lovastatin (4.9 (1.8-19) g/d; P = NS). None of the patients achieved partial remission during lovastatin therapy (P < 0.05 vs. probucol). CONCLUSION:
|
Authors | Martin Haas, Gert Mayer, Gerhard Wirnsberger, Herwig Holzer, Manfred Ratschek, Ullrich Neyer, Josef Neuweiler, Reinhard Kramar, Brigitte Schneider, Silvana Breiteneder-Geleff, Heinrich M Regele, Walter H Hörl, Dontscho Kerjaschki |
Journal | Wiener klinische Wochenschrift
(Wien Klin Wochenschr)
Vol. 114
Issue 4
Pg. 143-7
(Feb 28 2002)
ISSN: 0043-5325 [Print] Austria |
PMID | 12060980
(Publication Type: Comparative Study, Journal Article, Multicenter Study)
|
Chemical References |
- Anticholesteremic Agents
- Antioxidants
- Lovastatin
- Probucol
|
Topics |
- Adult
- Anticholesteremic Agents
(therapeutic use)
- Antioxidants
(adverse effects, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Glomerulonephritis, Membranous
(drug therapy)
- Humans
- Kidney Function Tests
- Lipid Peroxidation
(drug effects)
- Lovastatin
(therapeutic use)
- Male
- Middle Aged
- Probucol
(therapeutic use)
- Prospective Studies
- Proteinuria
(drug therapy)
- Treatment Outcome
|